ANX7 as a bio-marker in prostate and breast cancer progression

Meera Srivastava*, Lukas Bubendorf, Lisa Nolan, Mirta Glasman, Ximena Leighton, Georgina Miller, Wilfred Fehrle, Mark Raffeld, Ofer Eidelman, Olli P. Kallioniemi, Shiv Srivastava, Harvey B. Pollard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


The ANX7 gene codes for a Ca2+-activated GTPase, which has been implicated in both exocytotic secretion in cells and control of growth. In this review, we summarize information regarding increased tumor frequency in the Anx7 knockout mice, ANX7 growth suppression of human cancer cell lines, and ANX7 expression in human tumor tissue micro-arrays. The loss of ANX7 is significant in metastatic and hormone refractory prostate cancer compared to benign prostatic hyperplasia. In addition, ANX7 expression has prognostic value for predicting survival of breast cancer patients.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalDisease Markers
Issue number2
StatePublished - 2001
Externally publishedYes


Dive into the research topics of 'ANX7 as a bio-marker in prostate and breast cancer progression'. Together they form a unique fingerprint.

Cite this